Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Equillium, Inc. (EQ : NSDQ)
 
 • Company Description   
Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.32 Daily Weekly Monthly
20 Day Moving Average: 1,809,591 shares
Shares Outstanding: 35.72 (millions)
Market Capitalization: $11.47 (millions)
Beta: 1.86
52 Week High: $1.50
52 Week Low: $0.27
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -15.53% -19.28%
12 Week -32.99% -42.76%
Year To Date -57.10% -59.81%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2223 Avenida de la Playa Suite 105
-
LA JOLLA,CA 92037
USA
ph: 858-240-1200
fax: -
ir@equilliumbio.com http://www.equilliumbio.com
 
 • General Corporate Information   
Officers
Bruce D. Steel - Chief Executive Officer and President
Daniel M. Bradbury - Chairman of the Board of Directors
Jason A. Keyes - Chief Financial Officer
Penny Tom - Senior Vice President
Peter Colabuono - Director

Peer Information
Equillium, Inc. (CORR.)
Equillium, Inc. (RSPI)
Equillium, Inc. (CGXP)
Equillium, Inc. (BGEN)
Equillium, Inc. (GTBP)
Equillium, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29446K106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/14/25
Share - Related Items
Shares Outstanding: 35.72
Most Recent Split Date: (:1)
Beta: 1.86
Market Capitalization: $11.47 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.65 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.08
Price/Cash Flow: -
Price / Sales: 0.28
EPS Growth
vs. Year Ago Period: -200.00%
vs. Previous Quarter: -50.00%
Sales Growth
vs. Year Ago Period: -52.32%
vs. Previous Quarter: -63.88%
ROE
06/30/25 - -
03/31/25 - -74.34
12/31/24 - -37.61
ROA
06/30/25 - -
03/31/25 - -46.75
12/31/24 - -22.02
Current Ratio
06/30/25 - -
03/31/25 - 2.70
12/31/24 - 3.93
Quick Ratio
06/30/25 - -
03/31/25 - 2.70
12/31/24 - 3.93
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -19.62
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -19.62
Pre-Tax Margin
06/30/25 - -
03/31/25 - -44.81
12/31/24 - -18.75
Book Value
06/30/25 - -
03/31/25 - 0.30
12/31/24 - 0.54
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©